Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 40657, held by Zydus Pharms USA Inc. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 40657 (Hydroxychloroquine Sulfate), held by Zydus Pharms USA Inc, was first approved by FDA on Sep 21, 2007, with 5 approved supplements and 0 published complete response letters.
Hydroxychloroquine sulfate tablets is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. Treatment of rheumatoid arthritis in adults. Treatment of systemic lupus erythematosus in adults. Treatment of chronic discoid lupus erythematosus in adults. Limitations of Use: Hydroxychloroquine sulfate Tablets is not recommended for the: Treatment of complicated malaria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 21, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Jun 14, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jun 14, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jun 14, 2024 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jun 14, 2024 | Supplement 20Labeling · Standard review | Approved | None posted |
| Mar 23, 2020 | Supplement 7Labeling · Standard review | Approved | |
| Sep 21, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters